Adaptimmune Therapeutics plc

Equities

ADAP

US00653A1079

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.075 ^USD	+1.42%		+10.06%	+35.56%

Apr. 24	European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	MT
Apr. 23	European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading	MT

Adaptimmune Therapeutics plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

March 06, 2024 at 07:05 am EST

Adaptimmune Therapeutics plc reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported revenue was USD 0.231 million compared to USD 11.03 million a year ago. Net loss was USD 47.92 million compared to USD 29.25 million a year ago.

Basic loss per share from continuing operations was USD 0.24 compared to USD 0.18 a year ago.

Latest news about Adaptimmune Therapeutics plc

European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 24	MT
European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading	Apr. 23	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Friday Trading But End Week Down	Apr. 19	MT
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	Apr. 18	MT
Transcript : Adaptimmune Therapeutics plc - Analyst/Investor Day	Apr. 18
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 17	MT
European Equities Traded in the US as American Depositary Receipts Lower in Friday Trading	Apr. 12	MT
Adaptimmune Therapeutics Says Unit Gets Termination Notice for Strategic Collaboration With Genentech	Apr. 12	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading	Apr. 10	MT
European Equities Traded in the US as American Depositary Receipts Higher in Friday Trading, Close Out Week Lower	Apr. 05	MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading	Apr. 02	MT
European Equities Traded in the US as American Depositary Receipts Start Week Modestly Higher	Apr. 01	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Wednesday Trading	Mar. 27	MT
European Equities Traded in the US as American Depositary Receipts Kick Off Week Higher in Monday Trading	Mar. 25	MT
European Equities Traded in the US as American Depositary Receipts Slightly Higher in Friday Trading	Mar. 22	MT
European Equities Traded in the US as American Depositary Receipts Ease Wednesday	Mar. 20	MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Thursday Trading	Mar. 14	MT
European Equities Traded in the US as American Depositary Receipts Nudge Lower in Wednesday Trading	Mar. 13	MT
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading	Mar. 12	MT
ADRs Close Lower, Immuron Ltd. Declines 17.1%	Mar. 11	DJ
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading	Mar. 11	MT
ADRs Close Higher; Dada Nexus Ltd. Climbs 30%	Mar. 06	DJ
Transcript : Adaptimmune Therapeutics plc, Q4 2023 Earnings Call, Mar 06, 2024	Mar. 06
Adaptimmune Therapeutics plc Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 06	CI
Earnings Flash (ADAP) ADAPTIMMUNE THERAPEUTICS Reports Q4 Revenue $231,000, vs. Street Est of $26M	Mar. 06	MT

Chart Adaptimmune Therapeutics plc

Duration

Period

More charts

Company Profile

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. The Company is focused on providing cell therapies to people with cancer. Its engineered T-cell receptor (TCR) platform enables the engineering of T-cells to target and destroy cancers across multiple solid tumor types. Its cell therapy candidates include TCR T-cells and TruC T-cells. Its product candidates include afamitresgene autoleucel (afami-cel) and Lete-cel. The afamicel is a cell therapy that provides a treatment option for people with synovial sarcoma. The Company is in the process of transitioning lete-cel, which targets the NY-ESO antigen in people with synovial sarcoma and myxoid round cell liposarcoma (MRCLS). Its clinical pipeline includes SURPASS-III Phase II Trial with ADP-A2M4CD8 and SURPASS Phase I Trial with ADP-A2M4CD8. The Companyâs most advanced pre-clinical programs are for T-cell therapies directed to the PRAME target (ADP-600) and to CD70 (ADP-520). ADAP-600 is an engineered TCR T-cell.

Sector

Biotechnology & Medical Research

Calendar

2024-05-05 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Adaptimmune Therapeutics plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.075 USD

Average target price

3.6 USD

Spread / Average Target

+234.88%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ADAPTIMMUNE THERAPEUTICS PLC	+35.56%	275M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs